Science & Technology

Groundbreaking medical technology for accurate, fast & affordable screening of genetic disorders & beyond.

We have designed our technology to overcome current technical shortcomings and help healthcare systems move towards a more cost-effective and sustainable path for screening of genetic disorders.

gMendel® is the only AI cloud-based end-to-end IVD certified technology for accurate, real time & affordable screening of multiple rare diseases & beyond. Moreover, gMendel®’s technology is automated, transcending the need for bioinformatician‘s intervention, reducing the experimental errors & costs. This improves accessibility and has a potential to revolutionize genetic analysis without any change to current health care protocols.

See how the gMendel® technology compares to the other available technologies in the market

Currently, the diagnosis of genetic disorders relies on a set of non-accurate conventional techniques such as karyotyping/FISH, chromosomal microarrays (CMA), Sanger sequencing, comparative genome hybridization (CGH) arrays, MLPA- & PCR-based techniques and tandem mass spectrometry.

In addition, advanced technologies such as next generation sequencing and optical genome mapping (OGM) are still characterized by high complexity, high cost and high risk for patients, particularly in the case of Laboratory Developed Tests (LDTs), which are designed, manufactured and used within a single laboratory.

As a result, even after dozens of medical examinations, which take many years, significant number of patients are still misdiagnosed, creating a heavy human, economic and societal burden. There is an apparent unmet clinical need for better, faster and affordable screening/diagnosis of wide range of genetic disorders.

gMendel® technology is a groundbreaking, AI-powered solution that delivers accurate, fast, and affordable screening for genetic conditions at scale. By facilitating earlier interventions, it reduces patient suffering and has the potential to save healthcare systems billions globally. What sets gMendel® apart is its scalability and focus on mass genetic screening rather than individual diagnostics. Operating on a SaaS model, our platform processes hundreds of thousands of samples, significantly enhancing the speed and efficiency of genetic screening for large populations.

This approach not only expedites diagnosis but also democratizes access to genetic insights, enabling large-scale health interventions that are both feasible and financially sustainable. By seamlessly integrating genomics with AI, gMendel® surpasses existing technologies, delivering faster, more affordable, and superior results—all without requiring skilled personnel (i.e. Bioinformaticians for analysis and Geneticists for interpretation). In 2022, we became the world’s first IVD-certified technology for screening genetic disorders using long-read sequencing and AI, proudly achieving the CE mark.

  • Accurate, sensitive & specific
    It holds 97% analytical sensitivity, 99.1% analytical specificity and 98% accuracy, thus reducing inconclusive results and the need to repeat testing.
  • Cost-efficient
    It provides real-time and simultaneous analysis of up to 384 patient samples in less than 24 hours, which can bring down costs by a staggering 90%.
  • Rapid and scalable
    It is flexible and performs on-demand processing of several hundreds of patients’ samples per run due to our proprietary multilevel multiplexing method, Phivea®.
  • Reliable
    It can sequence any length of DNA fragment, from short to ultra-long, thus allowing more genetic variation characterization and versatility for to broad applications.
  • AI-driven
    It provides scalable genomic interpretation with a suite of ground-breaking algorithms. gMendel®’s technology is automated, transcending the need for bioinformatician’s intervention, reducing the experimental errors & costs. This improves accessibility and has a potential to revolutionize genetic analysis without any change to current health care protocols.
  • User friendly
    It requires minimal training and hands-on knowledge.
  • Safe
    It is CE-marked and certified as an IVD medical device product under the Directive 98/79/EC for In Vitro Diagnostic medical devices. Following versions of Phivea®️ platform shall be CE-marked and certified as an IVD medical device product under the Regulation (EU) 2017/746 (IVDR) of the European Parliament for In Vitro Diagnostic medical devices.
  • Secure
    It ensures highest security and patient data encryption through the use of private blockchains.